康芝药业(300086) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥109,945,844.25, a decrease of 40.90% compared to ¥186,023,819.29 in the same period last year[3] - The net profit attributable to shareholders was -¥46,239,789.41, representing a decline of 54.76% from -¥29,878,131.01 year-on-year[3] - Basic earnings per share decreased by 54.82% to -¥0.1028 from -¥0.0664 in the same period last year[5] - Net profit for Q1 2022 was a loss of ¥47,321,037.01, compared to a loss of ¥30,020,660.14 in Q1 2021, representing a 57% increase in losses[28] Cash Flow - The net cash flow from operating activities was -¥43,702,923.47, a significant decrease of 363.74% compared to ¥16,570,263.12 in the previous year[3] - Cash inflow from operating activities totaled ¥143,161,131.71, down from ¥236,867,174.81 in the previous year[32] - Investment activities resulted in a net cash outflow of -¥35,299,406.40, compared to -¥29,321,654.95 in Q1 2021[32] - In Q1 2022, the net cash flow from financing activities was -20,136,535.58 CNY, compared to -31,079,524.45 CNY in the same period last year[33] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,359,300,615.33, down 4.05% from ¥2,458,781,654.13 at the end of the previous year[5] - The equity attributable to shareholders decreased by 3.07% to ¥1,457,709,429.86 from ¥1,503,949,219.27 at the end of the previous year[5] - Total liabilities decreased to ¥1,077,300,777.63 from ¥1,128,437,643.13, a decline of 4.5%[24] - The total liabilities decreased to ¥852,979,787.56 from ¥905,139,789.35, reflecting a reduction of approximately 5.8%[28] Operational Changes - The company attributed the revenue decline to a reduction in the number of consolidated entities following the sale of its medical service business in July 2021[8] - Increased marketing expenses contributed to the significant drop in net profit and cash flow from operating activities[8] - Research and development expenses for Q1 2022 were ¥4,262,780.66, down 24% from ¥5,600,126.59 in Q1 2021[27] Government Support and Community Engagement - The company received government subsidies amounting to ¥3,882,005.61 during the reporting period[7] - The company actively participated in pandemic relief efforts by donating children's masks to support COVID-19 prevention in Hong Kong[19] Market Development - The company is pursuing further development in the European market, following a visit from Belgian officials expressing interest in collaboration[18] - The company has five drug research and development projects in the registration process, with three new drug projects currently undergoing clinical research[18] Training and Awareness - The company hosted an online training conference for nearly 1,000 participants, focusing on women's health and menopause awareness[18] Audit Status - The company did not conduct an audit for the Q1 2022 report[34]